Intellia Therapeutics, Inc. (NTLA)
NASDAQ$9.26+0.04 (0.43%)
Market Cap
$954.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
740 of 924
Rank in Industry
420 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
NTLA Insider Trading Activity
NTLA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $948,303 | 14 | 100 |
Related Transactions
| Bhanji Muna | director | 0 | $0 | 1 | $2,642 | $-2,642 |
| Verwiel Frank | director | 0 | $0 | 1 | $37,625 | $-37,625 |
| Dube Michael P | VP, Chief Accounting Officer | 0 | $0 | 2 | $54,959 | $-54,959 |
| Hicks Derek | EVP, Chief Business Officer | 0 | $0 | 1 | $79,194 | $-79,194 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 0 | $0 | 1 | $109,206 | $-109,206 |
| BASTA JAMES | EVP, General Counsel | 0 | $0 | 2 | $109,284 | $-109,284 |
| Clark Eliana | EVP, Chief Technical Officer | 0 | $0 | 4 | $112,480 | $-112,480 |
| Lebwohl David | EVP, Chief Medical Officer | 0 | $0 | 1 | $116,404 | $-116,404 |
| LEONARD JOHN M | President and CEO | 0 | $0 | 1 | $326,509 | $-326,509 |
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on …
Insider Activity of Intellia Therapeutics, Inc.
Over the last 12 months, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $948,303 worth of Intellia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $63.13M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $235,750 was made by SCHIERMEIER ANDREW (EVP, Dev and Corp Strategy) on 2019‑03‑06.
List of Insider Buy and Sell Transactions, Intellia Therapeutics, Inc.
| 2025-03-04 | Sale | BASTA JAMES | EVP, General Counsel | 2,572 0.0024% | $8.99 | $23,122 | +4.01% | |
| 2025-03-04 | Sale | Clark Eliana | EVP, Chief Technical Officer | 679 0.0006% | $8.99 | $6,104 | +4.01% | |
| 2025-01-29 | Sale | Bhanji Muna | director | 265 0.0003% | $9.97 | $2,642 | -1.19% | |
| 2025-01-03 | Sale | LEONARD JOHN M | President and CEO | 26,807 0.0263% | $12.18 | $326,509 | -16.69% | |
| 2025-01-03 | Sale | Lebwohl David | EVP, Chief Medical Officer | 9,557 0.0094% | $12.18 | $116,404 | -16.69% | |
| 2025-01-03 | Sale | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 8,966 0.0088% | $12.18 | $109,206 | -16.69% | |
| 2025-01-03 | Sale | BASTA JAMES | EVP, General Counsel | 7,074 0.007% | $12.18 | $86,161 | -16.69% | |
| 2025-01-03 | Sale | Clark Eliana | EVP, Chief Technical Officer | 7,422 0.0073% | $12.18 | $90,400 | -16.69% | |
| 2025-01-03 | Sale | Hicks Derek | EVP, Chief Business Officer | 6,502 0.0064% | $12.18 | $79,194 | -16.69% | |
| 2025-01-03 | Sale | Dube Michael P | VP, Chief Accounting Officer | 1,372 0.0013% | $12.18 | $16,711 | -16.69% | |
| 2025-01-02 | Sale | Clark Eliana | EVP, Chief Technical Officer | 556 0.0005% | $12.03 | $6,689 | -17.18% | |
| 2024-10-02 | Sale | Dube Michael P | VP, Chief Accounting Officer | 2,012 0.0018% | $19.01 | $38,248 | -31.97% | |
| 2024-07-01 | Sale | Clark Eliana | EVP, Chief Technical Officer | 405 0.0004% | $22.93 | $9,287 | -29.02% | |
| 2024-06-17 | Sale | Verwiel Frank | director | 1,505 0.0016% | $25.00 | $37,625 | -34.47% | |
| 2024-03-04 | Sale | BASTA JAMES | EVP, General Counsel | 2,297 0.0024% | $32.99 | $75,778 | -33.73% | |
| 2024-03-04 | Sale | Clark Eliana | EVP, Chief Technical Officer | 605 0.0006% | $32.99 | $19,959 | -33.73% | |
| 2024-01-08 | Sale | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 2,275 0.0025% | $28.87 | $65,682 | -23.71% | |
| 2024-01-03 | Sale | LEONARD JOHN M | President and CEO | 19,223 0.0215% | $29.46 | $566,310 | -22.09% | |
| 2024-01-03 | Sale | Lebwohl David | EVP, Chief Medical Officer | 5,843 0.0065% | $29.46 | $172,135 | -22.09% | |
| 2024-01-03 | Sale | BASTA JAMES | EVP, General Counsel | 3,805 0.0043% | $29.46 | $112,095 | -22.09% |
Total: 129
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Novartis Institutes for BioMedical Research, Inc. | 10 percent owner | 4129903 3.9896% | $38.08M | 1 | 1 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 2662180 2.5717% | $24.55M | 1 | 0 | <0.0001% |
| GORDON CARL L | director | 2662180 2.5717% | $24.55M | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 976214 0.943% | $9M | 1 | 0 | <0.0001% | |
| Temasek Holdings (Private) Ltd | 10 percent owner | 790527 0.7637% | $7.29M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$7,929,017 | 58 | 21.56% | $788.11M | |
$571,084,134 | 44 | 4.33% | $1.01B | |
$97,176 | 41 | 42.84% | $765.58M | |
$530,111,731 | 35 | 8.67% | $1.09B | |
$28,907,358 | 35 | 41.41% | $906.84M |
NTLA Institutional Investors: Active Positions
| Increased Positions | 194 | +69.04% | 26M | +27.47% |
| Decreased Positions | 122 | -43.42% | 17M | -18.52% |
| New Positions | 65 | New | 9M | New |
| Sold Out Positions | 52 | Sold Out | 9M | Sold Out |
| Total Postitions | 353 | +25.62% | 102M | +8.94% |
NTLA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ark Investment Management Llc | $126,492.00 | 12.05% | 12.54M | +280,946 | +2.29% | 2024-12-31 |
| Blackrock, Inc. | $109,554.00 | 10.44% | 10.86M | +1M | +11.1% | 2024-12-31 |
| Vanguard Group Inc | $102,818.00 | 9.8% | 10.19M | +562,249 | +5.84% | 2024-12-31 |
| State Street Corp | $52,525.00 | 5.01% | 5.21M | +62,164 | +1.21% | 2024-12-31 |
| Morgan Stanley | $38,489.00 | 3.67% | 3.81M | +1M | +48.08% | 2024-12-31 |
| Regeneron Pharmaceuticals, Inc. | $37,363.00 | 3.56% | 3.7M | +4M | New | 2024-12-31 |
| Sumitomo Mitsui Trust Group, Inc. | $30,196.00 | 2.88% | 2.99M | -156,736 | -4.98% | 2024-12-31 |
| Nikko Asset Management Americas, Inc. | $30,196.00 | 2.88% | 2.99M | -155,734 | -4.95% | 2024-12-31 |
| Citadel Advisors Llc | $25,165.00 | 2.4% | 2.49M | +2M | +152.07% | 2024-12-31 |
| Geode Capital Management, Llc | $24,107.00 | 2.3% | 2.39M | +45,930 | +1.96% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.